Navigation Links
Zyngenia, Inc. Raises $10 Million in Series A Funding
Date:11/4/2009

07. During his 16 years at MedImmune, it grew from a small biotechnology company into one of the five largest biotechnology companies in the world. Dr. Garland focuses on biopharmaceutical investments at NEA and is a Director of 3-V Biosciences, Cardioxyl Pharmaceuticals and Trevena, Inc. He trained in Internal Medicine and Infectious Diseases at the University of California, San Francisco. Prior to NEA, in addition to clinical practice at UCSF, Dr. Garland was with McKinsey & Company where he worked with biotechnology, pharmaceutical, medical device and diagnostics clients to evaluate investments, formulate product and corporate strategies and build businesses.

"We believe the unique Zyngenia platform has the potential to produce numerous therapeutic proteins, each with specificity for multiple targets, which may have significant advantages over both current single-specificity and bi-specific biologic drugs," said Mr. Mott. "We are excited about combining the therapeutic potential of this technology with a management team that has an impressive record of successfully building companies and developing biologics."

"It's rewarding to see my scientific technology platform coupled with the capabilities of Zyngenia's management team," said Dr. Barbas. "I look forward to working closely with the team and to leveraging the experience in biologic drug development and corporate strategy that Mr. Mott and Dr. Garland bring as we build the organization."

About Zyngenia, Inc.

Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibodies. The company uses proprietary patented technology to engineer single molecular entities that may interact with two or more targets. The company will initially focus its Zybody(TM) development on therapies for various cancers and autoimmune disorders. Zyngenia is headquartered in Rockville, Maryland. For
'/>"/>

SOURCE Zyngenia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LA JOLLA, Calif. , July 29, 2014 /PRNewswire/ ... therapy-based diagnostic and therapeutic company focused on extending the ... have hired Franz Och , Ph.D., an expert ... Chief Data Scientist. Och comes to HLI from Google ... of Google Translate. He will report directly to HLI ...
(Date:7/29/2014)... of researchers has created a new way of ... These surfaces, made by self-assembly of carbon nanotubes, ... including controllable mechanical stiffness and strength, or the ... , "We have demonstrated that mechanical forces can ... three-dimensional microstructures, and that we can independently control ...
(Date:7/29/2014)... 2014 Second generation biofuels are a viable ... fuels. However, as natural gas is very cheap, this is ... not as valuable as they could be in comparison to ... projects, has made it difficult for renewable energy developers to ... the ground. For these reasons, certain companies have shifted their ...
(Date:7/29/2014)... SANTA CLARA, Calif. , July 29, 2014 ... research services agreement with FORMA Therapeutics, Inc., to ... capabilities and proprietary fragment-based lead discovery platform for ... are really excited about the opportunity to work ... the fields of epigenetics and protein homeostasis. FORMA ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2
... Products with Herculex(R) XTRA Will Qualify for ... Lower Crop Insurance Rates, ... plant Pioneer(R) brand corn hybrids with the Herculex(R) XTRA,trait, including those ... crop insurance premium reductions in select states in 2009., DuPont ...
... has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo ... activity of selected AstraZeneca compounds. , ... EXTON, ... represents a significant opportunity for Melior to deliver value to AstraZeneca ...
... Product Developed from the VisEn-Merck & Co., Inc. ... Fluorescence Molecular Imaging Agent,Portfolio and Broadens Applications in ... BEDFORD, Mass., Aug. 19 VisEn Medical, ... research through medicine, announced,today the commercial launch of ...
Cached Biology Technology:DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 2DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 3VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent 2
(Date:7/29/2014)... 29, 2014 Research and Markets  has ... Intelligence (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies ... analyzing information about a company,s operations. BI help organizations ... business; for example, metrics on sales, production, and internal ...
(Date:7/29/2014)... to the edge of science, Clment Vidal takes on ... and the End: Does our universe have a beginning ... alone in the universe? What is the role of ... science and committed to philosophical rigor, the book presents ... is not an accident, but may well be the ...
(Date:7/29/2014)... UK overseas territory of Ascension Island, one of the ... a renaissance. , Writing in the journal Biodiversity ... and Ascension Island Government Conservation Department report that the ... Atlantic outpost has increased by more than 500 per ... as 24,000 nests are now estimated to be laid ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Book: 'The Beginning and the End' 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... peak in sight fitness peak, that is for ... Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, ... generating more than 50,000 generations. In a paper published in ... author and MSU graduate student in Lenski,s lab, compares it ...
... genetic signature of respiratory syncytial virus (RSV), the leading cause ... key step toward a better understanding of the immune response ... and a tool that could allow physicians to determine the ... from a team at The Research Institute at Nationwide Children,s ...
... may be more able to cope with dry conditions ... and Colorado State University used a computer model to ... the Amazon rainforest may be more able to withstand ... climate models. Many climate models over predict the ...
Cached Biology News:No peak in sight for evolving bacteria 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Amazon rainforest more able to withstand drought than previously thought 2
... StabilZyme SELECT Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a saline ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer is a diluent and stabilizer for ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... Stabilizer is a bovine protein-free alternative to ... aqueous solution that contains non-toxic chemicals in ... 6.6 - 7.2, and does not contain ... activity of antibodies and other biomolecules that ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: